The Significance of Myositis Autoantibodies in Idiopathic Inflammatory Myopathy Concomitant with Interstitial Lung Disease

Overview

Journal Neurol Sci

Specialty Neurology

Date 2020 Nov 19

PMID 33211209

Citations 8

Authors

Hung-Ling Huang

Wen-Chih Lin

Po-Yu Lin

Meng-Yu Weng

Yuan-Ting Sun

Affiliations

Soon will be listed here.

Abstract

Aim: This study identified factors associated with interstitial lung disease (ILD) in patients with idiopathic inflammatory myopathy (IIM) based on the latest classification and recent advances in autoantibody serology.

Methods: We retrospectively analyzed data of 173 patients who underwent complete myositis autoantibody serology examination in a medical center in Taiwan from July 2018 to February 2020. After exclusion of patients who did not receive a final diagnosis of IIM, clinical features, serology data, concomitant diseases, treatment, presence of respiratory failure, and mortality rate of the remaining 97 patients were analyzed.

Results: Of IIM patients in our cohort, 47.4% had ILD. ILD was significantly associated with subtypes of IIM, older age of onset, presence of mechanic's hand, and presence of anti-Jo-1 and anti-Ro52 antibodies. Among five IIM subtypes, overlap myositis (OM) and dermatomyositis (DM) were significantly associated with a higher prevalence rate of ILD (67.5% in OM and 53.3% in DM). Among patients with OM, the presence of anti-Jo-1 (100%), anti-PL-7 (100%), and anti-EJ antibodies (77.8%) was most significantly associated with ILD.

Conclusion: The latest classification of IIM, older age of onset, presence of mechanic's hand, and presence of anti-Jo-1 and anti-Ro52 antibodies were significantly associated with ILD. Among five IIM subtypes, OM and DM had higher prevalence rate of ILD. Among OM patients, the presence of anti-Jo-1, anti-EJ, and anti-PL-7 antibodies was significantly associated with ILD. The study results may help physicians to timely screen and monitor pulmonary function in high-risk groups.

Citing Articles

Association of anti-Ro52 autoantibody with interstitial lung disease in autoimmune diseases: a systematic review and meta-analysis.

Nayebirad S, Mohamadi A, Yousefi-Koma H, Javadi M, Farahmand K, Atef-Yekta R BMJ Open Respir Res. 2023; 10(1).

PMID: 38030264 PMC: 10689422. DOI: 10.1136/bmjresp-2023-002076.

Interstitial lung disease with and without progressive fibrosing phenotype in patients with idiopathic inflammatory myopathies: data from a large multicentric cohort.

Zanatta E, Cocconcelli E, Castelli G, Giraudo C, Fraia A, De Zorzi E RMD Open. 2023; 9(3).

PMID: 37541742 PMC: 10407351. DOI: 10.1136/rmdopen-2023-003121.

Predictors of progression in idiopathic inflammatory myopathies with interstitial lung disease.

Cao H, Huang J, Chang J, Zhu Y, Liang J, Sun C J Transl Int Med. 2023; 11(1):46-56.

PMID: 37533847 PMC: 10393057. DOI: 10.2478/jtim-2022-0029.

Incidence and prevalence of interstitial lung diseases worldwide: a systematic literature review.

Gupta R, Koteci A, Morgan A, George P, Quint J BMJ Open Respir Res. 2023; 10(1).

PMID: 37308252 PMC: 10277538. DOI: 10.1136/bmjresp-2022-001291.

Low serum level of citrullinated histone H3 in patients with dermatomyositis.

Wang W, Peng W, Wu S J Clin Lab Anal. 2023; 37(6):e24876.

PMID: 37003600 PMC: 10156100. DOI: 10.1002/jcla.24876.

References

Mimori T, Nakashima R, Hosono Y . Interstitial lung disease in myositis: clinical subsets, biomarkers, and treatment. Curr Rheumatol Rep. 2012; 14(3):264-74. DOI: 10.1007/s11926-012-0246-6. View

Kiely P, Chua F . Interstitial lung disease in inflammatory myopathies: clinical phenotypes and prognosis. Curr Rheumatol Rep. 2013; 15(9):359. DOI: 10.1007/s11926-013-0359-6. View

Schnabel A, Reuter M, Biederer J, Richter C, Gross W . Interstitial lung disease in polymyositis and dermatomyositis: clinical course and response to treatment. Semin Arthritis Rheum. 2003; 32(5):273-84. DOI: 10.1053/sarh.2002.50012. View

Lega J, Reynaud Q, Belot A, Fabien N, Durieu I, Cottin V . Idiopathic inflammatory myopathies and the lung. Eur Respir Rev. 2015; 24(136):216-38. PMC: 9487811. DOI: 10.1183/16000617.00002015. View

Johnson C, Pinal-Fernandez I, Parikh R, Paik J, Albayda J, Mammen A . Assessment of Mortality in Autoimmune Myositis With and Without Associated Interstitial Lung Disease. Lung. 2016; 194(5):733-7. PMC: 11678787. DOI: 10.1007/s00408-016-9896-x. View

Barba T, Mainbourg S, Nasser M, Lega J, Cottin V . Lung Diseases in Inflammatory Myopathies. Semin Respir Crit Care Med. 2019; 40(2):255-270. DOI: 10.1055/s-0039-1685187. View

Selva-OCallaghan A, Pinal-Fernandez I, Trallero-Araguas E, Milisenda J, Grau-Junyent J, Mammen A . Classification and management of adult inflammatory myopathies. Lancet Neurol. 2018; 17(9):816-828. PMC: 11646336. DOI: 10.1016/S1474-4422(18)30254-0. View

Schmidt J . Current Classification and Management of Inflammatory Myopathies. J Neuromuscul Dis. 2018; 5(2):109-129. PMC: 6004913. DOI: 10.3233/JND-180308. View

Lundberg I, de Visser M, Werth V . Classification of myositis. Nat Rev Rheumatol. 2018; 14(5):269-278. DOI: 10.1038/nrrheum.2018.41. View

10.

Leclair V, Lundberg I . New Myositis Classification Criteria-What We Have Learned Since Bohan and Peter. Curr Rheumatol Rep. 2018; 20(4):18. PMC: 5857275. DOI: 10.1007/s11926-018-0726-4. View

11.

Senecal J, Raynauld J, Troyanov Y . Editorial: A New Classification of Adult Autoimmune Myositis. Arthritis Rheumatol. 2017; 69(5):878-884. DOI: 10.1002/art.40063. View

12.

Fredi M, Cavazzana I, Franceschini F . The clinico-serological spectrum of overlap myositis. Curr Opin Rheumatol. 2018; 30(6):637-643. DOI: 10.1097/BOR.0000000000000536. View

13.

Benveniste O, Stenzel W, Allenbach Y . Advances in serological diagnostics of inflammatory myopathies. Curr Opin Neurol. 2016; 29(5):662-73. DOI: 10.1097/WCO.0000000000000376. View

14.

Satoh M, Tanaka S, Ceribelli A, Calise S, Chan E . A Comprehensive Overview on Myositis-Specific Antibodies: New and Old Biomarkers in Idiopathic Inflammatory Myopathy. Clin Rev Allergy Immunol. 2015; 52(1):1-19. PMC: 5828023. DOI: 10.1007/s12016-015-8510-y. View

15.

McHugh N, Tansley S . Autoantibodies in myositis. Nat Rev Rheumatol. 2018; 14(5):290-302. DOI: 10.1038/nrrheum.2018.56. View

16.

Li L, Wang H, Wang Q, Wu C, Liu C, Zhang Y . Myositis-specific autoantibodies in dermatomyositis/polymyositis with interstitial lung disease. J Neurol Sci. 2019; 397:123-128. DOI: 10.1016/j.jns.2018.12.040. View

17.

Hozumi H, Fujisawa T, Nakashima R, Johkoh T, Sumikawa H, Murakami A . Comprehensive assessment of myositis-specific autoantibodies in polymyositis/dermatomyositis-associated interstitial lung disease. Respir Med. 2016; 121:91-99. DOI: 10.1016/j.rmed.2016.10.019. View

18.

Stuhlmuller B, Schneider U, Gonzalez-Gonzalez J, Feist E . Disease Specific Autoantibodies in Idiopathic Inflammatory Myopathies. Front Neurol. 2019; 10:438. PMC: 6519140. DOI: 10.3389/fneur.2019.00438. View

19.

Chen F, Li S, Wang T, Shi J, Wang G . Clinical Heterogeneity of Interstitial Lung Disease in Polymyositis and Dermatomyositis Patients With or Without Specific Autoantibodies. Am J Med Sci. 2018; 355(1):48-53. DOI: 10.1016/j.amjms.2017.07.013. View

20.

Zhang L, Wu G, Gao D, Liu G, Pan L, Ni L . Factors Associated with Interstitial Lung Disease in Patients with Polymyositis and Dermatomyositis: A Systematic Review and Meta-Analysis. PLoS One. 2016; 11(5):e0155381. PMC: 4865124. DOI: 10.1371/journal.pone.0155381. View